Biomarker Endothelin-1 As Potential Marker of Cardiovascular Risk Interview with:
Dr. Matthias Bossard, MD
Clinical and Research Fellow Cardiology Division
Department of Medicine University Hospital Basel
Basel Switzerland

MedicalResearch: What is the background for this study? What are the main findings?

Dr. Bossard: Endothelin-1 (ET-1) and its pleiotropic effects have been implicated in the regulation of vascular and renal physiology as well as inflammation. Moreover, elevated ET-1 levels have been associated with endothelial dysfunction and atherosclerosis. Until now, data on the relationships between ET-1 and individual cardiovascular risk factors were scarce, especially from large-scale population based studies. This may be attributable to the previously used laboratory assays.The emergence of new ET-1 assays has facilitated ET-1 measurement in large populations.

Our main findings are that ET-1 levels are independently associated with several individual cardiovascular risk factors an overall cardiovascular risk in a large cohort of young and healthy adults.Specifically, ET-1 levels were significantly associated with systolic blood pressure, current smoking, glomerular filtration rate and high-sensitivity C-reactive protein.

MedicalResearch: What should clinicians and patients take away from your report?

Dr. Bossard: The novel ET-1 assay allows for easy measurement of ET-1 plasma levels. These levels correlate with major cardiovascular risk determinants even within the normal range. Thus, ET-1 may help to improve cardiovascular risk stratification. .

MedicalResearch: What recommendations do you have for future research as a result of this study?

Dr. Bossard: Plasma ET-1 may become a future marker for the cardiovascular risk prediction and determination of endothelial dysfunction. Prospective studies are necessary to evaluate the incremental value of ET-1 as a biomarker in clinical practice.


Plasma endothelin-1 and cardiovascular risk among young and healthy adults

 Bossard M1, Pumpol K2, van der Lely S2, Aeschbacher S2, Schoen T2, Krisai P2, Lam T2, Todd J3, Estis J3, Risch M4, Risch L5, Conen D6.

 Atherosclerosis. 2015 Jan 14;239(1):186-191. doi: 10.1016/j.atherosclerosis.2014.12.061. [Epub ahead of print]

[wysija_form id=”1″] Interview with:, & Dr. Matthias Bossard, MD (2015). Biomarker Endothelin-1 As Potential Marker of Cardiovascular Risk MedicalResearch.comm